1. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
by Kaiwen Chen, Matthew P. Cheng, Sarah P. Hammond, Hermann Einsele, and Francisco M. Marty
BloodAdv
Volume 2(16):
August 28, 2018
© 2018 by The American Society of Hematology

2. Systematic review flow diagram.
Kaiwen Chen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

3. Timelines of trials reviewed.
Kaiwen Chen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Forest plots summarizing outcomes of trials of antiviral prophylaxis vs placebo in HCT patients.
Forest plots summarizing outcomes of trials of antiviral prophylaxis vs placebo in HCT patients. (A) All-cause mortality. (B) CMV disease. (C) CMV infection (reactivation). (D) Preemptive therapy. BID, twice per day; df, degree of freedom.
Kaiwen Chen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Forest plots summarizing outcomes of trials of antiviral prophylaxis vs placebo in HCT patients.
Forest plots summarizing outcomes of trials of antiviral prophylaxis vs placebo in HCT patients. (A) All-cause mortality. (B) CMV disease. (C) CMV infection (reactivation). (D) Preemptive therapy. BID, twice per day; df, degree of freedom.
Kaiwen Chen et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology